Biopotency of vitamin E in lucerne meal for chickens

In order to estimate the biopotency of vitamin E in lucerne/alfalfa meal in comparison to that of dl-alpha-tocopheryl acetate (dl-alpha-Ta; all-rac-alpha-Ta) a study was conducted with newly hatched White Leghorn male chicks. An increase in the vitamin E level in the liver and plasma, and the prevention of nutritional encephalomalacia (NE) were used as criteria for biopotency. After a vitamin E depletion period of one week posthatching, the chicks continued on a semipurified, vitamin E free basal diet without vitamin E supplementation, or were repleted with graded levels of that vitamin for six weeks, provided as extracted lucerne oil or as dl-alpha-Ta. High performance liquid chromatography (HPLC) with fluorescence detection was used for the analysis of the vitamin E homologues. The diagnosis of NE was based on clinical and histopathological observations. A significant increase (P < 0.05) in vitamin E content in the liver and plasma was observed in response to dietary supplementation with both vitamin E sources. The linear increase both in the liver and plasma storage assays was associated with a reduced incidence of NE. The disease was totally prevented by a dietary supplement of 7.50 and 5.40 mg vitamin E/Kg feed provided as dl-alpha-Ta or lucerne oil, respectively. The natural biopotency of the vitamin E in lucerne meal compared with that of dl-alpha-Ta in the liver and plasma storage assays and in the prevention of NE was 123, 105 and 99%, respectively, as calculated by the slope ratio technique.

A prevalence survey of mental disorders among children in a rural Malaysian village

This is the first epidemiological survey of mental disorders among children in a Malaysian village. The WHO Research Questionnaire for Children (RQC) was used for initial screening followed by a semistructured interview, the Follow-up Interview for Children (FIC) at its second stage. Diagnosis was obtained by using Rutter's multi-axial classification. The prevalence rates obtained for the diagnostic categories were described in 3 age groups, in accordance with the age of attending school in Malaysia. Of 507 children screened aged 1-15, 6.1% were classified as having a mental disorder.

Histopathological and biochemical changes associated with selenium and vitamin E deficiency in chicks

One day old unsexed White Leghorn chicks obtained either from commercial hens fed adequate levels of selenium (Se) and vitamin E (VE) (Comm. chicks), or from hens depleted in both nutrients (Depl. chicks), were fed a low Se-VE semi-synthetic basal diet. The dietary Se content was kept constantly low, while graded levels of VE as dl-alpha-tocopheryl acetate (dl-alpha Ta), (0, 5, 10 or 15 mg VE/kg diet) were fed for six weeks. An efficient carry-over of Se and VE from hens to their progeny was observed by a significant increase in their muscle Se, liver Se-glutathione peroxidase (Se-GSH-Px), and VE content at hatching. In the Depl. chicks, signs of Se-VE deficiency, i.e. exudative diathesis (ED) were observed at hatching, indicating that the deficiency lesions had developed during the embryonic period, whereas these signs were not observed in Comm. chicks on the depletion diets until they were 2 weeks old. The VE supplemental level of 15 mg/kg was not adequate to provide a complete protection against ED. Exudative diathesis was associated with low levels of muscle Se, liver Se-GSH-Px and VE and was also accompanied by a simultaneous increase in the liver non-Se-GSH-Px. Autopsy findings and histopathological lesions were observed only in subcutaneous tissue and skeletal muscle. The subcutaneous tissue was edematous with hyaline vascular lesions and hemorrhages. The thigh muscles were more susceptible to deficiency lesions than were the breast muscles, and showed in acute stages degenerative processes of the muscle fibers including calcium deposits, vascular lesions and hemorrhages. In subacute and chronic cases, reparative changes and muscle damage may develop independently of the hyaline vasculosis. To prevent ED, adequate Se and VE in chick diet is essential after hatching, irrespective of their tissue reserves of both nutrients at 1 day of age.

Utilization of dietary sodium selenite, barley, oats and meat meal selenium by the chick

The biological availability of selenium (Se) in barley, oats and meat meal as compared to that in sodium selenite was determined by whole blood glutathione peroxidase (GSH-Px) activity and Se concentration depletion-repletion bioassays. One day old White Leghorn chicks, initially of low-Se status, were further depleted for Se by feeding a low-Se casein basal diet (0.03 mg Se/kg diet) adequate in vitamin E for the first two weeks of life. Repletion treatments of Se at graded levels supplemented by the natural sources or sodium selenite were then provided for 4 weeks. A multiple regression equation was calculated to relate the final whole blood GSH-Px activity and Se concentration to the dietary intake of Se. The percent biological availability of Se present in the natural sources was evaluated by slope ratio analyses in comparison to the standard, sodium selenite (100%). The activity of whole blood GSH-Px established a relative bioavailability for barley, oats and meat meal Se of 85, 41 and 25%, respectively (as mu kat/l), and 81, 51 and 17%, respectively (as mu kat/g Hb). The estimated bioavailability of Se in the different natural sources, as measured by blood Se concentration was: barley, 104%; oats, 99% and meat meal, 69% in comparison to that of sodium selenite. Thus, selenite Se was superior to the natural Se sources for the induction of GSH-Px activity. Barley Se appeared to be of higher biological value to chicks than did oats and meat meal Se. Even though meal Se was retained in appreciable amounts in chick blood, it showed the poorest utilization for the synthesis of blood GSH-Px.

Response of whole blood, erythrocyte and plasma vitamin E content to dietary vitamin E intake in the chick

Whole blood, red blood cells (RBC), and plasma vitamin E (VE) levels in chicks fed dietary VE (dl-alpha-tocopheryl acetate, dl-alpha Ta) supplementation in steps of 0.0, 5.0, 10.0, 15.0, 20.0 and 30.0 mg/Kg were determined to examine their usefulness as an index of VE status. The increase in VE level was significant and linear in whole blood (r = 0.90), RBC (r = 0.89) and plasma (r = 0.93) in response to dietary VE intake. There was a close correlation between VE in plasma vs whole blood (r = 0.90), plasma vs RBC (r = 0.91) and whole blood vs RBC (r = 0.95). The plasma VE content was 1.2-1.8 times greater than that of whole blood, and 6.6-12.5 times greater than that of RBC. The plasma total lipids content was not affected by the dietary VE intake, whereas the level of VE in the plasma total lipids was significantly increased with increasing supplementation. Alpha tocopherol was the major isomer (ca 92%) of VE in whole blood, RBC and plasma at hatching. The small proportions of beta-tocopherol (ca 2%), gamma-tocopherol (ca 5%) and alpha-tocotrienol (ca 1%) observed at 1 day of age had decreased or totally disappeared by 7 days of age after feeding the VE-free basal diet. The data showed that in the chick, the whole blood and RBC levels of VE were as sensitive and reliable indexes of dietary VE status as was that of the plasma.

Evidence that glutamate mediates axon-to-Schwann cell signaling in the squid

High-frequency stimulation (100 Hz) of isolated giant axons of the small squid Alloteuthis subulata and the large squid Loligo forbesi caused the periaxonal Schwann cell resting potential (Em = -40 mV) to hyperpolarize up to 11 mV in direct proportion to train duration and action potential amplitude. In both species, the Schwann cell also hyperpolarized up to 17 mV with the application of L-glutamate (10(-9) to 10(-6) M), in a dose-dependent manner. By contrast, in the presence of 10(-8) M d-tubocurarine (d-TC) to block the cholinergic component of the Schwann cell response, Schwann cells depolarized 8-9 mV during electrical stimulation of the axon or application of L-glutamate. In the presence of 10(-5) M 2-amino-4-phosphonobutyrate (2-APB), the hyperpolarization to glutamate and to axon stimulation was blocked, whereas the cholinergic (carbachol-induced) hyperpolarization was unaffected. In experiments with Alloteuthis, L-aspartate (10(-7) M) also caused a Schwann cell hyperpolarization, but this was not blocked by 2-APB. In tests with glutamate receptor agonists and antagonists, quisqualate (10(-5) M) produced a hyperpolarization blocked by 10(-4) M L-glutamic acid diethylester (GDEE), which also blocked the response to axonal stimulation. Kainic acid (10(-4) M) also caused a hyperpolarization, but n-methyl-D-aspartate (NMDA; 10(-4) M), ibotenate (10(-5) M), alpha-amino-3-hydroxy-5-methyl-isoxazole proprionate (AMPA; (10(-4) M), and isethionate (10(-5) M) had no effect.(ABSTRACT TRUNCATED AT 250 WORDS)

Studies of axon-glial cell interactions and periaxonal K+ homeostasis--III. The effect of anisosmotic media and potassium on the relationship between the resistance in series with the axon membrane and glial cell volume

The effect of anisosmotic physiological solutions and [K+]o on the resistance in series with the axon membrane were studied in medial giant axons of the crayfish, Procambarus clarkii, to determine if changes in series resistance are correlated with changes in glial cell volume and volume regulatory responses. Series resistance was estimated from computer analysed voltage waveforms generated by constant current and space clamp techniques using piggy-back axial wire current passing and glass pipette recording electrodes. Axons subjected to anisosmotic physiological solution in the range of 23 to 175% of isosmolar solution demonstrated that the series resistance of axons changes in a manner similar to that expected for a volume change in isolated cells. In hyperosmotic solution the series resistance changes biphasically, initially decreasing followed by a recovery of the series resistance, similar to the regulatory volume increase described for glial cells in culture. The increase in series resistance following the initial decrease is inhibited by bumetanide (0.1 mM). Ouabain (1 mM), an inhibitor of the volume decreasing Na-K pump, causes the series resistance to increase significantly above that seen for the no-drug control. Bumetanide, an inhibitor of the volume increasing Na-K-Cl cotransporter, inhibits the volume regulatory response to anisosmotic media. Treating the axon with three times normal external [K+] causes the series resistance to decrease approximately 15% while five times normal [K+] leads to a 15% increase in series resistance. Both ouabain and d-tubocurare (10(-p8) M) prevent the three-fold [K+]-induced decrease in series resistance while carbachol (10(-7) M) and bumetanide have little effect. On the other hand, ouabain enhances the five-fold [K+]-induced increase in series resistance while carbachol and bumetanide cause the five-fold [K+] response to be in a decreasing direction. d-Tubocurare has little effect on the five-fold [K+]-induced increase in series resistance. The study demonstrates that under the conditions of these experiments changes in series resistance are a reflection of changes in cell volume modulated by ouabain- and bumetanide-sensitive K+ uptake mechanisms. The effects of carbachol and d-tubocurare on the series resistance suggest that their effects are modulated through their actions on the glial cell membrane potential and the electrochemical gradient for K+, which in turn controls the amount of K+ that appears in the periaxonal space.(ABSTRACT TRUNCATED AT 400 WORDS)

Studies of axon-glial cell interactions and periaxonal K+ homeostasis--II. The effect of axonal stimulation, cholinergic agents and transport inhibitors on the resistance in series with the axon membrane

The small electrical resistance in series with the axon membrane is generally modeled as the intercellular pathway for current flow through the periaxonal glial (Schwann cell) sheath. The series resistance of the medial giant axon of the crayfish, Procambarus clarkii, was found to vary with conditions known to affect the electrical properties of the periaxonal glia. Series resistance was estimated from computer analysed voltage waveforms generated by axial wire-constant current and space clamp techniques. The average series resistance for all axons was 6.2 +/- 0.5 omega cm2 (n = 128). Values ranged between 1 and 30 omega cm2. The series resistance of axons with low resting membrane resistance (less than 1500 omega cm2) increased an average of 30% when stimulated for 45 s to 7 min (50 Hz) whereas the series resistance of high membrane resistance (greater than 1500 omega cm2) axons decreased an average of 10%. Carbachol (10(-7) M) caused the series resistance of low membrane resistance axons to decrease during stimulation but had no effect on high membrane resistance axons. d-Tubocurare (10(-8) M) caused the series resistance of high membrane resistance axons to increase during stimulation but had no effect on low membrane resistance axons. Bumetanide, a Na-K-Cl cotransport inhibitor and low [K+]o, prevented the stimulation-induced increase in series resistance of low membrane resistance axons but had no effect on the high membrane resistance axons. The results suggest that the series resistance of axons varies in response to the activity of the glial K+ uptake mechanisms stimulated by the appearance of K+ in the periaxonal space during action potential generation.(ABSTRACT TRUNCATED AT 250 WORDS)

Urinary C-peptide in the neonate correlates both to maternal glucose tolerance and to fetal size at birth

In 18 women with gestational diabetes the variables of an oral glucose tolerance test (fasting and 2-hour blood glucose values and area under the blood glucose curve) performed in the last trimester of pregnancy correlated significantly with the urinary C-peptide excretion during the first 12 hours of the life (r = 0.47, 0.71, and 0.60, respectively). In a combined group with 28 type II pregnant diabetic women there was also a significant correlation between the urinary C-peptide excretion of the infants and their skinfold. Assay of the urinary C-peptide excretion of the neonate, reflecting its insulin production, seems to be a sensitive parameter to study the influence of the maternal carbohydrate metabolism in the offspring.

Periaxonal K+ regulation in the small squid Alloteuthis. Studies on isolated and in situ axons

A novel giant axon preparation from the squid Alloteuthis is described. Properties of in situ and isolated axons are similar. Periaxonal K+ accumulation is a function of the physiological state of the animal and of the axon and its sheathing layers. Carefully dissected isolated axons, and axons in situ in a healthy mantle, show much less K+ accumulation than previously reported in squid. It is suggested that the Schwann cells are involved in the observed K+ regulation.

Bioavailability to chicks of selenium in barley, oats and meat meal

Day-old White Leghorn chicks deficient in selenium (Se) were fed a low Se basal diet (containing adequate level of vitamin E) for 2 weeks depletion period before they were given the experimental diets containing different levels of Se for 4 weeks. Dietary treatments contained 0.03, 0.06, 0.09 or 0.12 mg Se/kg as sodium selenite, barley, oats, meat meal or their extracted counterparts. Plasma GSH-Px activity was observed at weekly intervals, while the Se concentration of plasma and liver were determined at the end of the study. The biological availability of Se in the test ingredients was measured by the induction of plasma GSH-Px activity. In comparison to sodium selenite (100 %) it was: 77 % for barley, 80 % for extracted barley, 37 % for oats, 62 % for extracted oats, 20 % for meat meal, and 26 % for extracted meat meal. Using the retention of Se in plasma as a criterion, the following biological availability of Se was observed: barley 151 %; extracted barley 102 %; oats 90 %; extracted oats 107 %; meat meal 40 %; and extracted meat meal 47 %. Similarly, the efficiency of the test ingredients in increasing the Se concentration in liver was: barley 82 %; extracted barley 90 %; oats 67 %; extracted oats 98 %; meat meal 26 %; and extracted meat meal 31 %. The greater biopotency of the natural Se sources for increasing the Se concentration of the chick tissues than for inducing the plasma GSH-Px activity in comparison to sodium selenite, indicated that proportionally less amounts of the Se retained in the chick plasma from the natural sources were incorporated into the metabolic active form of Se, i.e., GSH-Px. Therefore, the plasma GSH-Px activity was suggested as the more reliable criterion to be used for the evaluation of the bioavailability of Se.

Comparative effect of selenium in wheat, barley, fish meal and sodium selenite for prevention of exudative diathesis in chicks

Groups af White Leghorn chicks obtained from dams deprived on selenium (Se), were fed from hatching a low-Se-vitamin E basal diet alone, or supplemented with 0.02, 0.04, 0.06 or 0.08 mg Se/kg diet, as sodium selenite (Na2SeO₃ · 5H₂O), wheat, barley or fish meal. Prevention of the Se-vitamin E deficiency responsive disease exudative diathesis (ED) as it was clinical observed, induction of the plasma Se dependent enzyme glutathione peroxidase (GSH-Px) activity, and Se concentration in the cardiac muscle were observed to be dietary Se level and source dependent. Slope ratio assay was applied to estimate the biological availability of Se in the natural sources relative to Se in sodium selenite. For the prevention of ED, the bioavailability of Se in wheat, barley and fish meal was 99, 85 and 80 %, respectively. The increase in the plasma GSH-Px activity revealed a bioavailability for Se in wheat, barley and fish meal of 79, 71 and 66 %, respectively. Using retention of Se in the cardiac muscle as the bioassay, a bioavailability of 108, 87 and 100 % was calculated for wheat, barley and fish meal Se, respectively.

Effect of a hydantoin prostaglandin analogue, BW245C, during oral dosing in man

Following an open pilot study, the effects of repeated oral doses of BW245C, a hydantoin prostaglandin analogue, were studied in man. Six healthy volunteers received 150 micrograms BW245C or placebo 6-hourly for 5 days according to a double blind randomised balanced design with 7 days interval between treatments. Measurements of headache, facial flushing, heart rate, blood pressure, systolic time intervals, ECG, platelet aggregation responses to ADP and of subjective effects were made before and 1 and 3 h after the first dose of BW245C/placebo on days 1, 3 and 5 of dosing. BW245C produced significantly (p less than 0.05) higher headache scores than placebo on days 3 and 5; facial flushing, nasal stuffiness and abdominal discomfort were more frequent on BW245C than placebo. Heart rate, derived from the ECG, was significantly (p less than 0.05) higher and pre-ejection period significantly (p less than 0.05) shorter on BW245C at 1 h after dosing on each day. Left ventricular ejection time index, QS2 index, PR interval, QRS duration and T wave height were unchanged. Heart rate, counted at the radial pulse, and systolic and diastolic blood pressure, all measured lying and standing, were similar for BW245C and placebo. Platelet aggregation responses were not significantly different between the two treatments. The results indicate that repeated oral doses of BW245C, sufficient to cause moderately uncomfortable subjective effects, do not inhibit platelet aggregation.

A chemically stable analogue, 9 beta-methyl carbacyclin, with similar effects to epoprostenol (prostacyclin, PGI2) in man

The effects of 9 beta-methyl carbacyclin, a chemically stable analogue of epoprostenol (prostacyclin, PGI2) were studied, in comparison with epoprostenol, both in vitro and in vivo in man. In vitro 9 beta-methyl carbacyclin and epoprostenol inhibited platelet aggregation induced by ADP, collagen, the endoperoxide analogue U46619 and arachidonic acid. The potency of 9 beta-methyl carbacyclin relative to epoprostenol was comparable in ADP and collagen-aggregated platelet rich plasma (PRP), 9 beta-methyl carbacyclin being 0.01 times as active as epoprostenol. The anti-aggregatory potencies of the two compounds were comparable in PRP and whole blood. The phosphodiesterase inhibitor isobutyl methyl xanthine enhanced the anti-aggregatory activity of both compounds in vitro. 9 beta-methyl carbacyclin and epoprostenol elevated platelet cyclic AMP, 9 beta-methyl carbacyclin being 0.04 times as active as epoprostenol. In a placebo controlled trial both drugs produces significant headache and facial flushing when compared with placebo. Nasal stuffiness, abdominal discomfort and nausea were reported on all three treatments. Both drugs caused significant and comparable increase in heart rate and decrease in pre-ejection (PEP) and PEP/left ventricular ejection time (LVET) ratio compared with placebo. Systolic and diastolic blood pressure, LVET and QS2 index were unchanged. Platelet aggregation responses to ADP were significantly inhibited by all three doses of both drugs compared with placebo. Bleeding time was significantly longer during epoprostenol infusion than either placebo or 9 beta-methyl carbacyclin infusion. Neither drug had significant effect, compared with placebo, on kaolin activated clotting time in PPP, PRP or in PRP in the presence of heparin, prothrombin time, partial thromboplastin time, thrombin clotting time, fibrinogen, fibrinogen degradation products or euglobulin clot lysis time. The pharmacodynamic effects and duration of action of 9 beta-methyl carbacyclin and of epoprostenol are similar; 9 beta-methyl carbacyclin is approximately 100 times less potent than epoprostenol in man.

Biopotency of vitamin E in barley

Investigations were carried out to establish the total biopotency of the natural vitamin E isomers in barley compared with that of DL-alpha-tocopheryl acetate. The chick was used as an experimental animal. Prevention of nutritional encephalomalacia (NE) and chick liver-storage and plasma-storage assays of vitamin E were the methods used in the study. The individual tocopherols and tocotrienols, both in the tissue samples and in the grain and barley oil, were analysed using high-pressure liquid chromatography (HPLC) with fluorescence detection. The diagnosis of NE was based on careful clinical and histopathological observations. It can be concluded from the results that full protection against NE in the chicks was obtained with a supplementation level of 7.5 mg DL-alpha-tocopheryl acetate/kg diet (i.e. a total vitamin E content of 11.20 mg/kg diet) or with a supplement of 8.7 g barley oil/kg diet (i.e. a total vitamin E content of 22.99 mg from barley oil/kg diet). This gave a biopotency factor of 0.49 for barley for prevention of NE of the chicks, as compared to that of DL-alpha-tocopheryl acetate. Using regression analysis a statistically linear relationship could be observed between the total dietary vitamin E level and the response, as measured by the total vitamin E content in the liver and plasma, both in the groups supplemented with DL-alpha-tocopheryl acetate and in the groups supplemented with corresponding amounts of vitamin E in barley oil. The liver and plasma responses to the total vitamin E in the barley-oil diet compared with those of the DL-alpha-tocopheryl acetate reference diet gave identical values for the regression coefficients, i.e. in both liver-storage and plasma-storage assays the value for slopes of dose-response lines was 0.37. This means that the biopotency of the total vitamin E in barley was 37% of that of dietary DL-alpha-tocopheryl acetate. Thus, barley is not as rich a source of vitamin E as could be supposed on the basis of the chemical determination of its total vitamin E content. It was possible to verify this experimentally established biopotency of 0.37 for the total vitamin E in barley by converting the chemically determined amounts of the vitamin E isomers in barley into DL-alpha-tocopheryl acetate equivalents by multiplying them with internationally accepted potency factors for the individual natural isomers (DL-alpha-tocopheryl acetate 1.00, D-alpha-tocopherol 1.49, D-beta-tocopherol 0.60, D-gamma-tocopherol 0.15, D-alpha-tocotrienol 0.37).(ABSTRACT TRUNCATED AT 400 WORDS)

Systolic time intervals: a review of the method in the non-invasive investigation of cardiac function in health, disease and clinical pharmacology

Measurement of systolic time intervals is a valuable, non-invasive procedure to assess left ventricular performance, particularly when influenced by drugs. In this review, we discuss various factors affecting systolic time intervals, the therapeutic implications of the technique and its place among other non-invasive tests of cardiac function.

Epoprostenol (prostacyclin,PGI2) increases apparent liver blood flow in man

When epoprostenol (prostacyclin, PGI2) is given by infusion to man, cardiac output is increased, and it appears that the gastrointestinal tract may receive a disproportionate share of this. We have used the clearance of indocyanine green dye to estimate liver blood flow in 8 healthy subjects. During an infusion of PGI2 at a dose of 5 ng/kg/min, apparent liver blood flow increased from 925 +/- 220 ml/min (Mean +/- s.d) to 1320 +/- 453 ml/min, an average increase of 41.1%. Significant changes in heart rate, headache, facial flushing, systolic blood pressure, and pulse pressure were noticed. We suggest that endogenous epoprostenol (PGI2) may be of importance in the physiological regulation of liver blood flow in man. As this dose of epoprostenol could be tolerated readily, epoprostenol therapy could prove a therapeutic advance in some liver disorders, particularly liver transplantation, and possibly in the therapy of certain drug overdoses.

Effects of intravenous epoprostenol on platelets and the cardiovascular system are not potentiated by dipyridamole

Normal subjects received infusions of epoprostenol (prostacyclin, PGI2) at doses of 2, 4, 6, and 8 ng/kg/min on each of two occasions after pretreatment with dipyridamole (400 mg/day for 3 days) or placebo. Baseline headache and bleeding time were increased and preejection period (PEP) shortened after dipyridamole. The baseline heart rate was increased on dipyridamole by an amount that correlated to the blood dipyridamole level. PGI2 infusion increased heart rate, systolic blood pressure (BP), pulse pressure, left ventricular ejection time index, and degree of flushing and severity of headache, and reduced diastolic BP, PEP, and T wave height. There was no apparent interaction between PGI2 and dipyridamole on these variables. PGI2 inhibited adenosine diphosphate-induced platelet aggregation and increased bleeding time. We conclude that, despite the synergism between dipyridamole and PGI2 that might be predicted and has been demonstrated in some animal experiments, no such interaction is apparent in normal humans after standard doses.

The cardiovascular and platelet effects of epoprostenol (prostacyclin, PGI2) are unaffected by beta-adrenoceptor blockade in man

1 Atenolol 0.2 mg/kg i.v., propranolol 0.2 mg/kg i.v. or placebo were given in a double-blind crossover study to six healthy male subjects, and the effects of a subsequent infusion of epoprostenol (prostacyclin, PGI2) 0-6 ng kg-1 min-1 monitored. 2 PGI2 caused a tachycardia, a fall in diastolic blood pressure, a rise in pulse pressure, reduction in pre-ejection period (PEP) and rise in left ventricular ejection time index (LVETI), headache and facial flushing at doses of PGI2 greater than 2 ng kg-1 min-1,, (P less than 0.05). 3 Beta-adrenoceptor blockade did not prevent the tachycardia in response to PGI2, and did not interact with any of the other dynamic effects of PGI2. 4 In vitro, PGI2 at 1 and 2 ng/ml inhibited platelet aggregation to ADP (P less than 0.01), although no significant effect on platelet aggregation was seen in the in vivo study. Atenolol and propranolol at a final concentration of 1 microgram/ml did not affect this in vitro study. Atenolol and propranolol at a final concentration of 1 microgram/ml did not affect in vitro effect of PGI2 on platelet aggregation. 5 Pretreatment with atropine 0.04 mg/kg i.v. in three subjects did not attenuate the tachycardia caused by PGI2 infusion, even though the baseline heart rate was increased. 6 Adverse effects to PGI2 infusion included sudden bradycardia, pallor and sweating, suggesting that the Bezold-Jarisch reflex seen in animals in response to PGI2 may also occur in humans. 7 Neither increased sympathetic drive nor vagal withdrawal are likely causes of the tachycardia following PGI2 infusion.

Cigarette smoking does not attenuate the cardiovascular effects of epoprostenol (prostacyclin) in humans

Infusion of epoprostenol (prostacyclin, PGI₂) in human subjects leads to a rise in pulse rate, a fall in diastolic pressure and a rise in pulse pressure. In three healthy subjects these responses to PGI₂ were identical before and after 30 min continuous cigarette smoking, and demonstrate that the attenuation of the PGI₂ response by smoking reported in rats does not occur in healthy humans.

Nephrotic syndrome

The nephrotic syndrome is clinical entity having multiple etiology. In the present study, 70 cases of nephrotic syndrome both in children and adults have been studied. The condition appears to be more common than thought of. The histological classification is helpful both in management and forecasting the prognosis. Steorid and cytotoxic drugs have been used in light negative glomerulonephritis and lupus nephritis producing nephrotic syndrome with good results. The other forms of of glomerulonephritis needs further study to be able to offer any specific therapy.